Advertisement

Clearmind Medicine Inc. CMND

Set alert

Price alert · CMND

All alert types
6.22 USD +0.37 +6.31%

At close · Oct 30

6.05 -0.17 -2.72%

After hours · Oct 30, 4:00 PM ET

Bid
6.11 × 2
Ask
6.61 × 1
5.83 Day range 6.50
5.72 52-week range 2,902.40
YTD
-95.71%
1 year
-99.79%
Open
5.83
Prev close
5.85
Mkt cap
3.16M
Vol
10.47K
Avg vol
58.53K
EPS
-461.20
P/E
0.00
Div yield
0.00%
More statistics
Low
5.83
High
6.50
Forward P/E
0.00
Beta
-1.51
Short ratio
1.88
Inst. own
16.02%
Dividend
0.00
Ex-div date
50-d avg
1.39
200-d avg
1.33
1y target
0.00

5D chart

Chart tools
Interval

Signals (31)
NameTimeAgo
MACD: Sell SignalOct 30, 12:10 PM1 day ago
SMA: BullishOct 30, 10:30 AM1 day ago
MACD: Buy SignalOct 30, 10:30 AM1 day ago
MACD: Sell SignalOct 30, 9:35 AM1 day ago
MACD: Buy SignalOct 29, 12:00 PM2 days ago
RSI: OversoldOct 29, 10:50 AM2 days ago
MACD: Sell SignalOct 29, 9:45 AM2 days ago
SMA: BearishOct 29, 9:40 AM2 days ago
SMA: BearishOct 29, 9:40 AM2 days ago
RSI: OverboughtOct 29, 9:30 AM2 days ago
MACD: Buy SignalOct 28, 3:10 PM3 days ago
MACD: Sell SignalOct 28, 2:35 PM3 days ago
MACD: Buy SignalOct 28, 1:25 PM3 days ago
SMA: BullishOct 28, 1:05 PM3 days ago
SMA: BearishOct 28, 12:35 PM3 days ago
RSI: OversoldOct 28, 12:35 PM3 days ago
MACD: Sell SignalOct 28, 11:55 AM3 days ago
SMA: BullishOct 28, 10:40 AM3 days ago
MACD: Buy SignalOct 28, 10:40 AM3 days ago
RSI: OverboughtOct 28, 10:40 AM3 days ago
MACD: Sell SignalOct 27, 3:40 PM4 days ago
SMA: BearishOct 27, 3:20 PM4 days ago
MACD: Buy SignalOct 27, 3:10 PM4 days ago
RSI: OverboughtOct 27, 3:10 PM4 days ago
MACD: Sell SignalOct 27, 10:20 AM4 days ago
SMA: BearishOct 27, 10:00 AM4 days ago
RSI: OverboughtOct 26, 3:50 PM5 days ago
MACD: Buy SignalOct 26, 1:55 PM5 days ago
RSI: OversoldOct 26, 12:55 PM5 days ago
SMA: BearishOct 26, 12:15 PM5 days ago
RSI: OversoldOct 26, 12:15 PM5 days ago

Key statistics

Market cap
5.35M
Enterprise value
-2.75M
Trailing P/E
0.00
Forward P/E
0.00
PEG ratio
0.00
Price / sales
0.00
Price / book
1.40
EPS (TTM)
-1.23
Beta
-1.51
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
162.86K
Total cash
7.68M
Total debt
60.90K
Return on equity
-267.90%
Shares outstanding
4.38M
Short % of float
4.72%
50-day average
1.39
200-day average
1.33

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
CMND Revenue — quarterly 0
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026
CMND Net income — quarterly -907.29K
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026
CMND EPS — quarterly -4.56
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026

About Clearmind Medicine Inc.

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders; and Dr. Glitter Pty Ltd to develop and commercialize the MEAI-based alcohol substitute and ActivCrystal technology. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada

News

Your note

Sign in to keep a note on CMND — it syncs with the Stock Master app.

Institution ownership

CMND institution ownership
Holder% heldSharesValueReported
Gotham Asset Management, LP10.70%339,008413.59KSep 29, 2024
AdvisorShares Investments, LLC5.38%170,641208.18KSep 29, 2024
UBS Group AG4.46%141,337172.43KSep 29, 2024
Cornerstone Wealth Group, LLC0.63%20,00024.40KSep 29, 2024
Citadel Advisors Llc0.56%17,72921.63KSep 29, 2024
HRT Financial LP0.40%12,75615.56KSep 29, 2024

Fund ownership

CMND fund ownership
Holder% heldSharesValueReported
AdvisorShares Trust-AdvisorShares Psychedelics ETF6.74%213,764260.79KOct 30, 2024
Advertisement